Diane Heiser

Diane Heiser has a strong background in translational research and medicine. Diane is currently working as the Vice President of Translational Research and Hematology at Prelude Therapeutics since August 2023. Prior to this role, they served as the Executive Director of Translational Medicine at the same company from February 2020 to August 2023.

Diane also has experience as an Advisor at Eigen Therapeutics starting from May 2022. Before that, Diane worked as a Consultant in the field of biotechnology, focusing on platform development for several biotech startups. This role lasted from September 2019 to March 2020.

Diane's earlier experiences include being the Scientific Founder and Chief Scientific Officer at Notable Labs from October 2015 to September 2019. During their time there, they led a team in leveraging precision medicine for patient stratification and therapy discovery in areas of high unmet need. Diane also established key partnerships and managed internal scientific research programs.

Before joining Notable Labs, Diane worked as a Postdoctoral Researcher at Stanford University School of Medicine, focusing on cancer stem cells. Diane also has experience as a Graduate Researcher at the University of Maryland School of Medicine, specializing in hematological malignancies and hematopoietic stem cells from 2007 to 2012.

Diane Heiser has a Bachelor's Degree in Molecular Biology from Princeton University, which they completed from 2002 to 2006. Diane then pursued a Doctor of Philosophy (PhD) in Cellular & Molecular Medicine at The Johns Hopkins University School of Medicine, where they studied from 2007 to 2012. From 2013 to 2016, Diane furthered their education by completing a postdoctoral program at Stanford University School of Medicine. The field of study for their postdoc is not specified.